EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Thérapie, 60 5 (2005) 441-460 Article's citations

Article cité par

La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).

Article cité :

Agomelatina: un nuevo enfoque farmacológico en el tratamiento de la depresión con traducción clínica

Cecilio Álamo, Francisco López-Muñoz and María José Armada
Psiquiatría Biológica 15 (4) 125 (2008)
https://doi.org/10.1016/S1134-5934(08)76482-0

Opposing Roles for 5-HT2A and 5-HT2C Receptors in the Nucleus Accumbens on Inhibitory Response Control in the 5-Choice Serial Reaction Time Task

Emma S J Robinson, Jeffrey W Dalley, David E H Theobald, et al.
Neuropsychopharmacology 33 (10) 2398 (2008)
https://doi.org/10.1038/sj.npp.1301636

Fine-tuning serotonin2c receptor function in the brain: Molecular and functional implications

Kelly A. Berg, William P. Clarke, Kathryn A. Cunningham and Umberto Spampinato
Neuropharmacology 55 (6) 969 (2008)
https://doi.org/10.1016/j.neuropharm.2008.06.014

In vivo Effect of Antidepressants on [3H]paroxetine Binding to Serotonin Transporters in Rat Brain

Subhash M. Nadgir and Manish Malviya
Neurochemical Research 33 (11) 2250 (2008)
https://doi.org/10.1007/s11064-008-9703-z

The loss of methyl-CpG binding protein 1 leads to autism-like behavioral deficits

A. M. Allan, X. Liang, Y. Luo, et al.
Human Molecular Genetics 17 (13) 2047 (2008)
https://doi.org/10.1093/hmg/ddn102

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

William J. Thomsen, Andrew J. Grottick, Frederique Menzaghi, Hazel Reyes-Saldana, Stephen Espitia, Diane Yuskin, Kevin Whelan, Michael Martin, Michael Morgan, Weichao Chen, Hussien Al-Shamma, Brian Smith, Derek Chalmers and Dominic Behan
The Journal of Pharmacology and Experimental Therapeutics 325 (2) 577 (2008)
https://doi.org/10.1124/jpet.107.133348

Physical Interaction of Calmodulin with the 5-Hydroxytryptamine2C Receptor C-Terminus Is Essential for G Protein-independent, Arrestin-dependent Receptor Signaling

Marilyne Labasque, Eric Reiter, Carine Becamel, et al.
Molecular Biology of the Cell 19 (11) 4640 (2008)
https://doi.org/10.1091/mbc.e08-04-0422

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

Anne Dekeyne, Clotilde Mannoury la Cour, Alain Gobert, et al.
Psychopharmacology 199 (4) 549 (2008)
https://doi.org/10.1007/s00213-008-1177-9

Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms

Robert L. Gannon and Mark J. Millan
Psychopharmacology 195 (3) 325 (2007)
https://doi.org/10.1007/s00213-007-0903-z

Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism

Stephen M. Stahl
The International Journal of Neuropsychopharmacology 10 (05) (2007)
https://doi.org/10.1017/S1461145707008000

Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with α/β-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors

Mark J. Millan and Anne Dekeyne
The International Journal of Neuropsychopharmacology 10 (05) (2007)
https://doi.org/10.1017/S1461145706007309

In vivo Schild regression analyses using nonselective 5-HT2C receptor antagonists in a rat operant behavioral assay

Ellen A. Walker, Edward K. Brown and Steven N. Sterious
Psychopharmacology 193 (2) 187 (2007)
https://doi.org/10.1007/s00213-007-0769-0

Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors

Pia Weikop, Jan Kehr and Jørgen Scheel-Krüger
Journal of Psychopharmacology 21 (8) 795 (2007)
https://doi.org/10.1177/0269881107077347

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

Mark J. Millan
Pharmacology & Therapeutics 110 (2) 135 (2006)
https://doi.org/10.1016/j.pharmthera.2005.11.006

Bombesin Receptors as a Novel Anti-Anxiety Therapeutic Target: BB1Receptor Actions on Anxiety through Alterations of Serotonin Activity

Zul Merali, Tania Bédard, Nick Andrews, Ben Davis, Alexander T. McKnight, M. Isabel Gonzalez, Martyn Pritchard, Pam Kent and Hymie Anisman
The Journal of Neuroscience 26 (41) 10387 (2006)
https://doi.org/10.1523/JNEUROSCI.1219-06.2006

Anti-obesity pharmacotherapy: Future perspectives utilising 5-HT2C receptor agonists

Alice C. Dutton and Nicholas M. Barnes
Drug Discovery Today: Therapeutic Strategies 3 (4) 577 (2006)
https://doi.org/10.1016/j.ddstr.2006.11.005

Could agomelatine be the ideal antidepressant?

SR Pandi-Perumal, Venkatramanujan Srinivasan, PD Cardinali and MJ Monti
Expert Review of Neurotherapeutics 6 (11) 1595 (2006)
https://doi.org/10.1586/14737175.6.11.1595